Current evidence on prevention and management of contrast-induced nephropathy

Area of Science:

• Radiology
• Nephrology
• Medical Imaging

Background:

• Contrast-induced nephropathy (CIN) is a significant concern in medical imaging.
• Most CIN research focuses on intraarterial contrast media administration.
• Intravenous contrast administration also poses a risk, particularly for patients with renal impairment.

Purpose of the Study:

• To evaluate the incidence of CIN following intravenous contrast medium administration.
• To assess the efficacy of volume expansion, iodixanol, and acetylcysteine in preventing CIN.
• To provide guidance on contrast media selection for CT scans.

Main Methods:

• Review of prospective randomized studies on CIN incidence after intravenous contrast administration.
• Analysis of risk factors and preventative strategies for CIN.
• Evaluation of specific contrast agents (iodixanol) and adjunct therapies (acetylcysteine).

Main Results:

• Intravenous contrast administration carries a similar CIN risk as intraarterial administration, especially in high-risk patients.
• Volume expansion is effective in reducing CIN risk.
• No evidence supports the use of iodixanol or acetylcysteine for preventing CIN in intravenous contrast administration.
• Gadolinium-based contrast media are not recommended for CT procedures.

Conclusions:

• CIN risk is comparable between intravenous and intraarterial contrast administration routes.
• Volume expansion is a recommended strategy for CIN prevention.
• Current evidence does not support iodixanol or acetylcysteine for preventing CIN with intravenous contrast.
• Alternative contrast agents should be considered for CT to avoid potential nephrotoxicity.